Brief: Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion Of Phase 1 Study Of DYRK1A Inhibitor FRTX-02
13/09/2022 14:57
Sept 13 (Reuters) - Fresh Tracks Therapeutics Inc FRTX.O :
* FRESH TRACKS THERAPEUTICS INITIATES MULTIPLE ASCENDING
DOSE
PORTION OF PHASE 1 STUDY OF DYRK1A INHIBITOR FRTX-02
* FRESH TRACKS THERAPEUTICS INC - ON TRACK TO REPORT SAD AND
MAD
TOPLINE RESULTS FROM FRTX-02 PHASE 1 STUDY BY EARLY 2023
Source text for Eikon: ID:nGNX56CdKS
Further company coverage: FRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx